Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Laroprovstat Dose X STP, Laroprovstat STP
Laroprovstat · 2 trials · 1 indication
To compare the effect of treatment with laroprovstat/rosuvastatin versus rosuvastatin on LDL-C at 8 weeks
| Arm | Type | Description |
|---|---|---|
| laroprovstat/rosuvastatin dose 1 | EXPERIMENTAL | Patient will receive a daily dose of laroprovstat/rosuvastatin 1 and a placebo to match rosuvastatin 1 |
| rosuvastatin dose 1 | ACTIVE_COMPARATOR | Patient will receive a daily dose of rosuvastatin 1 and placebo to match laroprovstat/rosuvastatin 1 |
| laroprovstat/rosuvastatin dose 2 | EXPERIMENTAL | Patient will receive a daily dose of laroprovstat/rosuvastatin 2 and a placebo to match rosuvastatin 2 |
| rosuvastatin dose 2 | ACTIVE_COMPARATOR | Patient will receive a daily dose of rosuvastatin 2 and placebo to match laroprovstat/rosuvastatin 2 |
| laroprovstat/rosuvastatin dose 3 | EXPERIMENTAL | Patient will receive a daily dose of laroprovstat/rosuvastatin 3 and a placebo to match rosuvastatin 3 |
| rosuvastatin dose 3 | ACTIVE_COMPARATOR | Patient will receive a daily dose of rosuvastatin 3 and placebo to match laroprovstat/rosuvastatin 3 |
| laroprovstat/rosuvastatin dose 4 | EXPERIMENTAL | Patient will receive a daily dose of laroprovstat/rosuvastatin 4 and a placebo to match rosuvastatin 4 |
| rosuvastatin dose 4 | ACTIVE_COMPARATOR | Patient will receive a daily dose of rosuvastatin 4 and placebo to match laroprovstat/rosuvastatin 4 |
| Laroprovstat | ACTIVE_COMPARATOR | The patient will receive a daily dose of Laroprovstat |
| Placebo | PLACEBO_COMPARATOR | The patient will receive a daily dose of Placebo |
| Laroprovstat/Rosuvastatin dose combination 1 | EXPERIMENTAL | The patient will receive a daily dose of Laroprovstat/Rosuvastatin 1 |
| Laroprovstat/Rosuvastatin dose combination 2 | EXPERIMENTAL | The patient will receive a daily dose of Laroprovstat/Rosuvastatin 2 |
| Name | Type | Description |
|---|---|---|
| laroprovstat/rosuvastatin 1 | COMBINATION_PRODUCT | daily oral dose of the laroprovstat/rosuvastatin 1 |
| laroprovstat/rosuvastatin 2 | COMBINATION_PRODUCT | daily oral dose of the laroprovstat/rosuvastatin 2 |
| laroprovstat/rosuvastatin 3 | COMBINATION_PRODUCT | daily oral dose of the laroprovstat/rosuvastatin 3 |
| laroprovstat/rosuvastatin 4 | COMBINATION_PRODUCT | daily oral dose of the laroprovstat/rosuvastatin 4 |
| Placebo to match laroprovstat/rosuvastatin 1,2,3 | DRUG | Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 1,2,3 |
| Placebo to match laroprovstat/rosuvastatin 4 | DRUG | Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 4 |
| Rosuvastatin 1 | DRUG | daily oral dose of rosuvastatin 1 |
| Rosuvastatin 2 | DRUG | daily oral dose of rosuvastatin 2 |
| Rosuvastatin 3 | DRUG | daily oral dose of rosuvastatin 3 |
| Rosuvastatin 4 | DRUG | daily oral dose of rosuvastatin 4 |
| Placebo to match Rosuvastatin | DRUG | daily oral dose of placebo to match rosuvastatin |
| Laroprovstat | DRUG | daily oral dose of the Laroprovstat |
| Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1 | DRUG | daily oral dose of the Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1 |
| Placebo to match Laroprovstat/Rosuvastatin 2 | DRUG | daily oral dose of the Placebo to match Laroprovstat/Rosuvastatin 2 |
Inclusion Criteria: * Participant must be ≥ 18 years of age * Participants must be on a stable dose of all background LLTs * The stable statin dose should be judged as their maximally tolerated dose * Participants should have either history of a clinical ASCVD event or be at increased risk for a fi...
Laroprovstat is an investigational small molecule being developed for the treatment of hypercholesterolaemia, a condition of elevated cholesterol in the blood. It is being studied both as a standalone therapy and in fixed-dose combinations with rosuvastatin and with ezetimibe, with the goal of lowering LDL-C in patients with hypercholesterolaemia.
Laroprovstat is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is running the Phase 3 clinical program evaluating laroprovstat and its fixed-dose combinations in patients with hypercholesterolaemia across multiple countries including the United States, Canada, and several European nations.
Laroprovstat is in Phase 3 clinical development. Two Phase 3 trials are currently recruiting, with a combined planned enrollment of 800 patients. The program includes both active-controlled and placebo-controlled designs, and the studies are randomized and double-blind, evaluating laroprovstat alone and in fixed-dose combinations.
Laroprovstat is being evaluated in two Phase 3 trials. NCT07619131 is a 600-patient study comparing fixed-dose laroprovstat/rosuvastatin against laroprovstat, rosuvastatin, and placebo in LLT-naive patients. NCT07619118 is a 200-patient study comparing fixed-dose laroprovstat/rosuvastatin against rosuvastatin in patients with hypercholesterolaemia. Both trials are currently recruiting.